Status: In progress | |
Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
|
Medicine details |
|
Medicine name | dupilumab (Dupixent®) |
Formulation | 200 mg solution for injection, 300 mg solution for injection |
Reference number | 4017 |
Indication | As above |
Company | Sanofi-Aventis Ltd |
BNF chapter | Respiratory system |
Submission type | Licence extension for paediatric use |
Status | In progress |
AWMSG meeting date | TBC |
Date of issue | TBC |
Commercial arrangement | PAS |
Further information |